Ebola Rapid Lateral Flow Test Previewed at the 2015 AACC Annual Meeting
|
By LabMedica International staff writers Posted on 27 Jul 2015 |

Image: The AtomoRapid lateral flow immunoassay diagnostic platform (Photo courtesy of Atomo Diagnostics).
A novel rapid point-of-care assay for the diagnosis of Ebolavirus infection was introduced at the 2015 AACC Annual Meeting & Clinical Lab Expo (Atlanta, GA, USA).
BBI Solutions (Cardiff, United Kingdom), a biotech company that supplies a range of mouse monoclonal antibodies for detecting the Ebola virus, announced from its booth (3665) at the AACC Annual meeting that that it would soon release a rapid test for Ebola in association with the technology transfer company Ploughshare Innovations (Stockbridge, United Kingdom).
The test is built around the highly regarded Atomo Diagnostics (Sydney, Australia) lateral flow technology and provides a result in approximately 20 minutes. Five Ebola antibodies against the Zaire and Sudan strains of Ebolavirus have been tested successfully with this system. BBI Solutions also provides a panel comprising 13 different monoclonal antibodies, to the Zaire and Sudan strains.
The lateral flow test has already been evaluated in the field. In trials in Sierra Leone a 100% detection rate was achieved for 138 participants. At low positive levels the test achieved 100% sensitivity and 92% specificity, and at a high positive, 100% sensitivity and 97% specificity. This performance suggests that the BBI Solutions assay is potentially more sensitive and specific than other lateral flow or dipstick type assays currently available.
Leigh Thomas, chief commercial officer at BBI Solutions, said, “BBI has developed high performance lateral flow tests for some of the world’s leading diagnostic companies for over 25 years. Our expertise and flexibility has allowed us to quickly deploy a team and develop a rapid test in nine months which, based on field testing, promises to have an immediate and positive impact on the Ebola crisis. We are pleased that our test will meet an immediate need in the field and ultimately improve the lives of others.”
Related Links:
2015 AACC Annual Meeting & Clinical Lab Expo
BBI Solutions
Atomo Diagnostics
BBI Solutions (Cardiff, United Kingdom), a biotech company that supplies a range of mouse monoclonal antibodies for detecting the Ebola virus, announced from its booth (3665) at the AACC Annual meeting that that it would soon release a rapid test for Ebola in association with the technology transfer company Ploughshare Innovations (Stockbridge, United Kingdom).
The test is built around the highly regarded Atomo Diagnostics (Sydney, Australia) lateral flow technology and provides a result in approximately 20 minutes. Five Ebola antibodies against the Zaire and Sudan strains of Ebolavirus have been tested successfully with this system. BBI Solutions also provides a panel comprising 13 different monoclonal antibodies, to the Zaire and Sudan strains.
The lateral flow test has already been evaluated in the field. In trials in Sierra Leone a 100% detection rate was achieved for 138 participants. At low positive levels the test achieved 100% sensitivity and 92% specificity, and at a high positive, 100% sensitivity and 97% specificity. This performance suggests that the BBI Solutions assay is potentially more sensitive and specific than other lateral flow or dipstick type assays currently available.
Leigh Thomas, chief commercial officer at BBI Solutions, said, “BBI has developed high performance lateral flow tests for some of the world’s leading diagnostic companies for over 25 years. Our expertise and flexibility has allowed us to quickly deploy a team and develop a rapid test in nine months which, based on field testing, promises to have an immediate and positive impact on the Ebola crisis. We are pleased that our test will meet an immediate need in the field and ultimately improve the lives of others.”
Related Links:
2015 AACC Annual Meeting & Clinical Lab Expo
BBI Solutions
Atomo Diagnostics
Latest AACC 2015 News
- Automated Molecular Diagnostics System Presented at AACC 2015
- Portable Molecular Diagnostics System Unveiled At 2015 AACC
- Expanded Steroid Control Launched at the 2015 AACC Annual Meeting
- Innovative New Technology to Provide Plastic-Exterior Components with Glass Interior, Presented at AACC 2015
- Eco-Friendly Immunoassay Reagents Featured at AACC 2015
- Low Cost Point-of-Care DNA Amplification Test for Chlamydia Infection Demonstrated at the 2015 AACC Annual Meeting
- Inexpensive Multipurpose Point-of-Care Analyzer Unveiled at 2015 AACC Annual Meeting
- State-of-the-Art Automated Laboratory Systems Highlighted at the 2015 AACC Annual Meeting
- Siemens Showcases Multiple New IVD Solutions at AACC 2015
- New HPLC Quadruples Clinical Throughput Capabilities, Displayed at AACC 2015
- Diagnostic Test that Measures Active Renin in Hypertension Displayed at the 2015 AACC Annual Meeting
- Hair Testing May Offer Insights into Asthma-Related Complications in Pregnancy
- Two Newly Developed Tests May Better Diabetes Diagnosis and Monitoring
- CE Marking of Theranostic Monitoring Test Announced at 2015 AACC Annual Meeting
- AACC: Better Quality and Patient-Friendliness Needed in Direct Testing
- Clinical Chemistry Instruments and Reagents Under Scrutiny at the 2015 AACC Annual Meeting
Channels
Clinical Chemistry
view channelNew Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read more
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read moreMolecular Diagnostics
view channel
Ultra-Sensitive DNA Test Identifies Relapse Risk in Aggressive Leukemia
Acute myeloid leukemia (AML) is a rare but aggressive blood cancer in which relapse after allogeneic stem cell transplant remains a major clinical challenge, particularly for patients with NPM1-mutated disease.... Read more
Blood Test Could Help Detect Gallbladder Cancer Earlier
Gallbladder cancer is one of the deadliest gastrointestinal cancers because it is often diagnosed at an advanced stage when treatment options are limited. Early symptoms are minimal, and current screening... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Hidden Gut Viruses Linked to Colorectal Cancer Risk
Colorectal cancer (CRC) remains a leading cause of cancer mortality in many Western countries, and existing risk-stratification approaches leave substantial room for improvement. Although age, diet, and... Read more
Three-Test Panel Launched for Detection of Liver Fluke Infections
Parasitic liver fluke infections remain endemic in parts of Asia, where transmission commonly occurs through consumption of raw freshwater fish or aquatic plants. Chronic infection is a well-established... Read morePathology
view channel
Molecular Imaging to Reduce Need for Melanoma Biopsies
Melanoma is the deadliest form of skin cancer and accounts for the vast majority of skin cancer-related deaths. Because early melanomas can closely resemble benign moles, clinicians often rely on visual... Read more
Urine Specimen Collection System Improves Diagnostic Accuracy and Efficiency
Urine testing is a critical, non-invasive diagnostic tool used to detect conditions such as pregnancy, urinary tract infections, metabolic disorders, cancer, and kidney disease. However, contaminated or... Read moreTechnology
view channel
Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
More than 7 million Americans live with Alzheimer’s disease, and related health and long-term care costs are projected to reach nearly USD 400 billion in 2025. The disease has no cure, and symptoms often... Read more
AI-Powered Biomarker Predicts Liver Cancer Risk
Liver cancer, or hepatocellular carcinoma, causes more than 800,000 deaths worldwide each year and often goes undetected until late stages. Even after treatment, recurrence rates reach 70% to 80%, contributing... Read more
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreIndustry
view channel
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more








